• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement.

作者信息

Rigaud Charlotte, Abbou Samuel, Ducassou Stephane, Simonin Mathieu, Le Mouel Lou, Pereira Victor, Gourdon Stephanie, Lambilliotte Anne, Geoerger Birgit, Minard-Colin Veronique, Brugieres Laurence

机构信息

Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif.

Department of Pediatric Oncology and Hematology, Bordeaux University hospital, Bordeaux.

出版信息

Haematologica. 2022 Sep 1;107(9):2255-2260. doi: 10.3324/haematol.2021.280081.

DOI:10.3324/haematol.2021.280081
PMID:35586965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9425319/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05e3/9425319/d94d7d2b297a/1072255.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05e3/9425319/d94d7d2b297a/1072255.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05e3/9425319/d94d7d2b297a/1072255.fig1.jpg

相似文献

1
Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement.下一代ALK抑制剂在复发或进展性ALK阳性间变性大细胞淋巴瘤合并中枢神经系统受累患者中引起深度且持久的反应。
Haematologica. 2022 Sep 1;107(9):2255-2260. doi: 10.3324/haematol.2021.280081.
2
KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth.KRCA-0008 抑制 ALK 阳性间变大细胞淋巴瘤的生长。
Invest New Drugs. 2020 Oct;38(5):1282-1291. doi: 10.1007/s10637-020-00896-4. Epub 2020 Jan 20.
3
Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.艾乐替尼治疗复发或难治性间变性淋巴瘤激酶阳性间变大细胞淋巴瘤：一项开放标签的 II 期试验。
Cancer Sci. 2020 Dec;111(12):4540-4547. doi: 10.1111/cas.14671. Epub 2020 Oct 28.
4
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.克唑替尼治疗儿童难治性实体瘤或间变大细胞淋巴瘤的安全性和活性：儿童肿瘤学组 1 期联盟研究。
Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.
5
[Primary central nervous system ALK-positive anaplastic large cell lymphoma: a clinicopathological analysis of four cases].[原发性中枢神经系统ALK阳性间变性大细胞淋巴瘤：4例临床病理分析]
Zhonghua Bing Li Xue Za Zhi. 2023 Oct 8;52(10):1031-1033. doi: 10.3760/cma.j.cn112151-20230314-00193.
6
Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?ALK 阳性间变大细胞淋巴瘤的治疗是否应根据微小残留病灶进行分层？
Pediatr Blood Cancer. 2021 Jun;68(6):e28982. doi: 10.1002/pbc.28982. Epub 2021 Mar 9.
7
Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.阻断克唑替尼诱导的 ALK 阳性间变大细胞淋巴瘤中 BCL2 的上调可触发与细胞死亡相关的自噬。
Haematologica. 2019 Jul;104(7):1428-1439. doi: 10.3324/haematol.2017.181966. Epub 2019 Jan 24.
8
Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.阿来替尼和依维莫司对 ALK 阳性间变大细胞淋巴瘤生长抑制的协同作用。
Anticancer Res. 2020 Mar;40(3):1395-1403. doi: 10.21873/anticanres.14081.
9
Isolated Central Nervous System Progression During Systemic Treatment With Brentuximab Vedotin Monotherapy in a Pediatric Patient With Recurrent ALK-negative Anaplastic Large Cell Lymphoma.在接受 Brentuximab Vedotin 单药治疗的儿童复发性 ALK 阴性间变性大细胞淋巴瘤患者中，孤立性中枢神经系统进展。
J Pediatr Hematol Oncol. 2021 Aug 1;43(6):e864-e866. doi: 10.1097/MPH.0000000000001914.
10
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.第二届儿科间变性淋巴瘤激酶（ALK）抑制治疗儿科恶性肿瘤策略论坛：与欧洲药品管理局合作，在美国食品药品监督管理局的参与下，共同开展 ACCELERATE 研究。
Eur J Cancer. 2021 Nov;157:198-213. doi: 10.1016/j.ejca.2021.08.022. Epub 2021 Sep 15.

引用本文的文献

1
Anaplastic large cell lymphoma in children and adolescents.儿童和青少年间变性大细胞淋巴瘤
Br J Haematol. 2025 Aug;207(2):336-349. doi: 10.1111/bjh.20154. Epub 2025 May 12.
2
Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era.靶向药物时代小儿复发性/难治性ALK阳性间变性大细胞淋巴瘤的治疗与转归
Blood Adv. 2025 Mar 25;9(6):1356-1365. doi: 10.1182/bloodadvances.2024014745.
3
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs).

本文引用的文献

1
Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial.儿童间变性大细胞淋巴瘤的预后因素：国际ALCL99试验的长期结果
Cancers (Basel). 2020 Sep 24;12(10):2747. doi: 10.3390/cancers12102747.
2
Neuro-meningeal relapse in anaplastic large-cell lymphoma: incidence, risk factors and prognosis - a report from the European intergroup for childhood non-Hodgkin lymphoma.神经脑膜复发的间变大细胞淋巴瘤：发生率、危险因素和预后——来自欧洲儿童非霍奇金淋巴瘤分组的报告。
Br J Haematol. 2021 Mar;192(6):1039-1048. doi: 10.1111/bjh.16755. Epub 2020 Jul 9.
3
CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series.
目前和即将出现的针对常见 PTCL 亚型（PTCL，NOS；ALCL；和 TFHs）的治疗方法。
Blood. 2024 Oct 31;144(18):1887-1897. doi: 10.1182/blood.2023021789.
4
Primary Anaplastic-Lymphoma-Kinase-Positive Large-Cell Lymphoma of the Central Nervous System: Comprehensive Review of the Literature.原发性间变性淋巴瘤激酶阳性中枢神经系统大细胞淋巴瘤：文献综述
J Clin Med. 2023 Dec 5;12(24):7516. doi: 10.3390/jcm12247516.
5
Future Perspective for ALK-Positive Anaplastic Large Cell Lymphoma with Initial Central Nervous System (CNS) Involvement: Could Next-Generation ALK Inhibitors Replace Brain Radiotherapy for the Prevention of Further CNS Relapse?初始累及中枢神经系统（CNS）的ALK阳性间变性大细胞淋巴瘤的未来展望：下一代ALK抑制剂能否替代脑放疗以预防CNS进一步复发？
Pediatr Rep. 2023 May 26;15(2):333-340. doi: 10.3390/pediatric15020029.
6
Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.ALK+ ALCL 患者来源异种移植模型揭示了布加替尼治疗的临床前潜力。
Br J Haematol. 2023 Sep;202(5):985-994. doi: 10.1111/bjh.18953. Epub 2023 Jun 25.
高危复发 ALK 阳性间变大细胞淋巴瘤应用长春碱或靶向治疗时的中枢神经系统进展：病例系列研究。
Pediatr Blood Cancer. 2018 Jun;65(6):e27003. doi: 10.1002/pbc.27003. Epub 2018 Mar 7.
4
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.克唑替尼在ALK阳性肿瘤（非小细胞肺癌除外）中的长期疗效：一项1b期开放标签研究。
Am J Hematol. 2018 May;93(5):607-614. doi: 10.1002/ajh.25043. Epub 2018 Feb 8.
5
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.本妥昔单抗治疗复发或难治性系统性间变性大细胞淋巴瘤患者的5年结果
Blood. 2017 Dec 21;130(25):2709-2717. doi: 10.1182/blood-2017-05-780049. Epub 2017 Oct 3.
6
ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin.伴有中枢神经系统受累的ALK阴性间变性大细胞淋巴瘤需要的不仅仅是维布妥昔单抗。
Ann Hematol. 2016 Oct;95(10):1725-6. doi: 10.1007/s00277-016-2746-3. Epub 2016 Jul 27.
7
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.ALK 阳性晚期非小细胞肺癌患者中克唑替尼与化疗的颅内疗效：PROFILE 1014 研究结果。
J Clin Oncol. 2016 Aug 20;34(24):2858-65. doi: 10.1200/JCO.2015.63.5888. Epub 2016 Mar 28.
8
Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.克唑替尼停药后ALK阳性淋巴瘤的突然复发。
N Engl J Med. 2016 Jan 7;374(1):95-6. doi: 10.1056/NEJMc1511045.
9
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.克唑替尼耐药的间变性淋巴瘤激酶（ALK）重排非小细胞肺癌（NSCLC）患者中艾乐替尼针对全身疾病和脑转移的安全性和活性：一项 1/2 期研究剂量探索部分的结果。
Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.
10
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.克唑替尼治疗儿童难治性实体瘤或间变大细胞淋巴瘤的安全性和活性：儿童肿瘤学组 1 期联盟研究。
Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.